Reviewing Everpure (NYSE:P) & Ainos (NASDAQ:AIMD)

Everpure (NYSE:P) and Ainos (NASDAQ:AIMD) are both technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Volatility & Risk

Everpure has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Comparatively, Ainos has a beta of 2.47, suggesting that its share price is 147% more volatile than the S&P 500.

Profitability

This table compares Everpure and Ainos’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Everpure	5.94%	19.06%	5.89%
Ainos	N/A	-217.50%	-67.87%

Earnings & Valuation

This table compares Everpure and Ainos”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Everpure	$3.66 billion	14.08	$188.18 million	$0.73	211.99
Ainos	$120,000.00	74.41	-$14.77 million	($2.52)	-0.48

Everpure has higher revenue and earnings than Ainos. Ainos is trading at a lower price-to-earnings ratio than Everpure, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Everpure and Ainos, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Everpure	1	3	17	0	2.76
Ainos	1	0	0	0	1.00

Everpure presently has a consensus price target of $140.00, indicating a potential downside of 9.53%. Given Everpure’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Everpure is more favorable than Ainos.

Institutional and Insider Ownership

83.4% of Everpure shares are held by institutional investors. 5.1% of Everpure shares are held by insiders. Comparatively, 9.8% of Ainos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Everpure beats Ainos on 11 of the 14 factors compared between the two stocks.

About Everpure

Pure Storage, Inc. provides data storage technologies, products, and services in the United States and internationally. The company’s Purity software is shared across its products and provides enterprise-class data services, such as data reduction, data protection, and encryption, as well as storage protocols, including block, file, and object. Its products portfolio includes FlashArray for block-oriented storage, addressing databases, applications, virtual machines, and other traditional workloads; FlashArray//XL; and FlashArray//C, an all-QLC flash array. The company also provides FlashBlade, a solution for unstructured data workloads of various types; FlashStack that combines compute, network, and storage to provide an infrastructure platform; FlashRecover, an all-flash modern data-protection solution; and AIRI, a full-stack AI-ready infrastructure. In addition, it offers evergreen storage subscription, Pure as-a-Service, and Cloud Block Store, as well as Portworx a cloud-native Kubernetes data management solution It also offers technical and professional, training and education, and certification services. The company sells its products and subscription services through direct sales force and channel partners. The company was formerly known as OS76, Inc. and changed its name to Pure Storage, Inc. in January 2010. Pure Storage, Inc. was incorporated in 2009 and is headquartered in Mountain View, California.

About Ainos

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women’s health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.